A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer

অনুরূপ উপাদানগুলি

• A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer
  অনুযায়ী: Baughman, Jan, অন্যান্য
  প্রকাশিত: (2015)
• Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3
  অনুযায়ী: Powderly, John, অন্যান্য
  প্রকাশিত: (2015)
• Ipilimumab: A First-in-Class  T-Cell Potentiator for Metastatic Melanoma
  অনুযায়ী: Bartosz Chmielowski
  প্রকাশিত: (2013-01-01)
• Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
  অনুযায়ী: Chmielowski, Bartosz
  প্রকাশিত: (2013)
• Tumor Mutation Burden and Efficacy of Nivolumab Monotherapy and in Combination With Ipilimumab in Small Cell Lung Cancer
  অনুযায়ী: Hellmann, Matthew D., অন্যান্য
  প্রকাশিত: (2018)